July 15, 2021 PAO-07-21-CL-06
Mesenchymal stromal or stem cells (MSCs) are typically adherent cells that can both self-renew and differentiate into different types of cells, including those with adipogenic, osteogenic, and chondrogenic lineages.1 Additionally, MSCs exhibit immunomodulatory behavior, exhibit low immunogenicity, and can induce regeneration and maintain homeostasis, largely due to their ability to move to target tissues.
Most notably, human MSCs (hMSCs) have been demonstrated to be safe following their use for the last two decades in tens of thousands of patients and hundreds of clinical trials. From 2011 to 2020, over 1500 hMSC clinical trials were posted, 126 of which were late-stage (phase II/III or later) and 16 of which were post-market (phase IV) studies.2
Despite their attractive properties, natural hMSCs transplanted into patients often do not achieve the maximum benefits possible, because some of the cells are destroyed within the transplanted microenvironment, others have lost their ability to differentiate and multiply, and ultimately only a small percentage of the cells are able to migrate to the target site.1
One method of addressing the limitations of natural hMSCs is to modify them using gene-editing tools to produce stable, robust allogeneic or off-the-shelf therapies.3 The goal is to improve cellular survival, increase migration, homing, and adhesion to target sites and to avert senescence, poor cell division, or growth.1
Gene editing can be accomplished using a number of different tools, including CRISPR-Cas, TALENs, meganucleases (homing endonucleases), zinc finger nucleases (ZFNs), synthetic single-stranded DNA templates, such as recombinant AAV, or other technologies.4
With respect to cell therapies, gene editing has been mainly used with T cells and hematopoietic stem cells (HSCs), but its application to MSCs is increasing. Since 2000, the number of both grants and patent filings related to the gene editing of MSCs has increased dramatically.4
Gene editing also enables the production of off-the-shelf allogeneic hMSC drug products with innate therapeutic properties combined with robustness and manufacturing scalability for the treatment of inflammatory, autoimmune, neurodegenerative, cardiovascular, and infectious diseases and for wound healing, pain management, and tissue/organ engineering.
Indeed, hMSCs are well-established starting materials for off-the-shelf cell therapy products. These allogeneic treatments are produced using standardized, quality-controlled raw materials and developed according to a transparent regulatory path that has already been navigated by companies with approved products. Allogeneic hMSCs have been shown to realistically scale at consistent population doubling levels (PDLs) to meet clinical translation needs, streamlining development time, cost, and regulatory burden.
While the first IND-enabling clinical studies for cell therapies based on gene-edited hMSCs have not yet occurred, they are anticipated to take place within the next several years.5
Modified genes must be introduced into the hMSCs via either transduction or transfection. Different methods can be used, including a variety of viral and non-viral mechanisms, each with its own set of tradeoffs. For example, viral methods are typically more efficient at delivering the gene editing machinery across cell membranes and into the cytoplasm and have lower overt toxicity, but can exhibit greater off-target nuclease activity by the gene editor. Researchers continue to explore the use of different viruses and non-viral methods, including hybrid methods wherein the gene editor is introduced into cells via physical or chemical methods and virus is used to introduce the recombinant DNA sequence. Because different primary cell types respond differently to different transfection methods, trial and error are used to empirically determine the most efficient method that affords a pool of hMSCs within which the vast majority have been properly modified.
Traditionally, however, genetic modification of primary cells like hMSCs has resulted in low efficiency of transfer accompanied by higher cell toxicities. Primary cells tends to have limited growth potential and short life spans and can be difficult to maintain under typical culture conditions. The result is low yields of hMSCs with the desired genetic modification. The ability to edit a relatively small number of cells (millions) and expand them afterward is key to the cost effectiveness of gene editing.
For the best results, cells need to be homogeneous and used as soon as possible. A large excess of the delivery vehicle is typically used (e.g., a high viral agent multiplicity of infection (MOI)) to ensure an acceptable transfer efficiency. For transduction using viral vectors, for instance, that means higher amounts of viral particles are required, leading to significantly higher costs. Extensive optimization is also necessary with respect to media, sera, supplements, and process conditions, which adds to the time and costs required for traditional genetic modification.
RoosterGEM™ is a highly efficient complete genetic engineering medium formulated to increase transduction efficiency and reduce viral agent MOI and associated costs in one simplified, off-the-shelf medium created by RoosterBio, a platform technology company focused on creating tools to accelerate the development of a sustainable regenerative medicine industry.
Engineered from the ground up, RoosterGEM was built as part of a simplified, efficient, and economical hMSC genetic engineering platform. It is configured to require less manual intervention, saving process time and reducing opportunity for human error.
In addition, the simplified transduction workflow and translation-friendly formats made possible by RoosterGEM not only reduce key LV and raw material costs, but also allow researchers and product developers to custom-engineer their clinical transduction protocols more efficiently and focus on their viral agent so they can reach the clinic faster.
Use of RoosterGEM alone or in combination with RoosterBio’s high-volume, xeno-free hMSCs resulted in two- to four-fold increases in percent-modified hMSCs derived from multiple tissue sources (see Figures 1–3). This high performance enables a reduction in viral particle concentration and reagent expense, adding up to more than 50% cost reduction versus traditional transduction reagents in a model genetic engineering process involving banked, pre-expansion cells.
Figure 3: Lentiviral transduction efficiency at Low MOI (rLV.EF1.ZsGreen1-9, MOI = 4, Flash Therapeutics) resulted in >95% positive cells without a significant decrease in hMSC expansion performance over three passages. Key critical hMSC identity and functional performance attributes were also maintained (data not shown).
Another significant benefit enabled by RoosterGEM involves the recovery of hMSCs following transduction. No matter how high the transduction efficiency is, the process can hit a significant roadblock if the viability of cells or their expansion is significantly impacted following transduction. While cell growth is slowed during transduction, there is no impact on recovery or expansion, and a high percent positivity is maintained over three subsequent passages, with expansion performance for cells transduced using RoosterGEM matching controls (Figure 4).
Although originally developed with a focus on hMSCs and LV, RoosterGEM’s potent enhancement of transduction efficiency can also be applied to a broader range of clinically relevant, primary cell types and gene transfer toolkits. In addition, RoosterGEM is readily translatable into a cGMP-compliant version that RoosterBio now has in development.
RoosterGEM was not developed in isolation. It is part of a complete system for hMSC genetic engineering and post-modification expansion to support preclinical product and engineered cell bank development developed by RoosterBio. RoosterBio’s industrialized supply chain of high-volume cGMP hMSC products includes high-volume xeno-free hMSCs, ultra-productive expansion media, and cGMP-compatible processes.
When used in combination with this end-to-end genetic engineering hMSC platform, RoosterGEM helps streamline transient or integrated gene transfer, de-risk product and process development, and accelerate the path to clinical translation, including expediting Investigational New Drug (IND) filings.
In fact, gene-modified hMSCs produced using RoosterBio’s platform can be the ideal cellular “chassis” for rapidly prototyped lead products manufactured using a drop-in, accelerated production process. Designed and tested engineered gene sequences assembled into bifunctional “apps” and “app systems” can be delivered into the hMSC cellular genome, after which the enhanced cells can be expanded and deployed.
This process could be adapted to a “plug-and-play” GMP process to produce off-the-shelf, clinical-grade hMSC materials. MSCs from a donor bank would be transduced/transfected with the gene apps and yield cells that would be expanded and frozen as pre-expanded doses. Those pre-doses would, when needed, be expanded to the final dose and then delivered to the patient for infusion.
David is Scientific Editor in Chief of the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content, in addition to serving as Scientific Research Director for That's Nice. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University in 1999 and a Ph.D. in Genetics and Development from Columbia University in 2008.